These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 12904587)

  • 1. Peanut allergy: recent advances.
    Simons FE
    Pediatr Res; 2003 Sep; 54(3):291-2. PubMed ID: 12904587
    [No Abstract]   [Full Text] [Related]  

  • 2. Recent advances in the diagnosis and therapy of peanut allergy.
    Sheikh SZ; Burks AW
    Expert Rev Clin Immunol; 2013 Jun; 9(6):551-60. PubMed ID: 23730885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II, randomized, double‑blind, parallel‑group, placebo‑controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy.
    Sampson HA; Leung DY; Burks AW; Lack G; Bahna SL; Jones SM; Wong DA
    J Allergy Clin Immunol; 2011 May; 127(5):1309-10.e1. PubMed ID: 21397314
    [No Abstract]   [Full Text] [Related]  

  • 4. Two approaches to peanut allergy.
    Metzger H
    N Engl J Med; 2003 Mar; 348(11):1046-8. PubMed ID: 12637615
    [No Abstract]   [Full Text] [Related]  

  • 5. Oral immunotherapy for peanut allergy shows promise but questions remain.
    Kmietowicz Z
    BMJ; 2014 Jan; 348():g1265. PubMed ID: 24480396
    [No Abstract]   [Full Text] [Related]  

  • 6. [Anti-IgE therapy--possible way in severe nut allergy. The hidden allergen in candy is a danger for risk groups].
    Hedlin G; Foucard T
    Lakartidningen; 2003 Apr; 100(15):1314-5. PubMed ID: 12739399
    [No Abstract]   [Full Text] [Related]  

  • 7. The eliciting dose of peanut in double-blind, placebo-controlled food challenges decreases with increasing age and specific IgE level in children and young adults.
    van der Zee T; Dubois A; Kerkhof M; van der Heide S; Vlieg-Boerstra B
    J Allergy Clin Immunol; 2011 Nov; 128(5):1031-6. PubMed ID: 21885095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Children with peanut allergy recognize predominantly Ara h2 and Ara h6, which remains stable over time.
    Flinterman AE; van Hoffen E; den Hartog Jager CF; Koppelman S; Pasmans SG; Hoekstra MO; Bruijnzeel-Koomen CA; Knulst AC; Knol EF
    Clin Exp Allergy; 2007 Aug; 37(8):1221-8. PubMed ID: 17651153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peanut allergy: lymphocyte response to peanut extract.
    Samartín S; Marcos A; Chandra RK
    Forum Nutr; 2003; 56():155-8. PubMed ID: 15806842
    [No Abstract]   [Full Text] [Related]  

  • 10. Peanut allergy.
    Hourihane JO
    Pediatr Clin North Am; 2011 Apr; 58(2):445-58, xi. PubMed ID: 21453812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does severity of low-dose, double-blind, placebo-controlled food challenges reflect severity of allergic reactions to peanut in the community?
    Hourihane JO; Grimshaw KE; Lewis SA; Briggs RA; Trewin JB; King RM; Kilburn SA; Warner JO
    Clin Exp Allergy; 2005 Sep; 35(9):1227-33. PubMed ID: 16164452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peanut epitopes for IgE and IgG4 in peanut-sensitized children in relation to severity of peanut allergy.
    Flinterman AE; Knol EF; Lencer DA; Bardina L; den Hartog Jager CF; Lin J; Pasmans SG; Bruijnzeel-Koomen CA; Sampson HA; van Hoffen E; Shreffler WG
    J Allergy Clin Immunol; 2008 Mar; 121(3):737-743.e10. PubMed ID: 18234310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peanut allergy: recurrence and its management.
    Fleischer DM; Conover-Walker MK; Christie L; Burks AW; Wood RA
    J Allergy Clin Immunol; 2004 Nov; 114(5):1195-201. PubMed ID: 15536431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of high-dose peanut oral immunotherapy with factors predicting outcome.
    Anagnostou K; Clark A; King Y; Islam S; Deighton J; Ewan P
    Clin Exp Allergy; 2011 Sep; 41(9):1273-81. PubMed ID: 21414048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel immunoassay using recombinant allergens simplifies peanut allergy diagnosis.
    Codreanu F; Collignon O; Roitel O; Thouvenot B; Sauvage C; Vilain AC; Cousin MO; Decoster A; Renaudin JM; Astier C; Monnez JM; Vallois P; Morisset M; Moneret-Vautrin DA; Brulliard M; Ogier V; Castelain MC; Kanny G; Bihain BE; Jacquenet S
    Int Arch Allergy Immunol; 2011; 154(3):216-26. PubMed ID: 20861643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Basophil allergen threshold sensitivity, CD-sens, IgE-sensitization and DBPCFC in peanut-sensitized children.
    Glaumann S; Nopp A; Johansson SG; Rudengren M; Borres MP; Nilsson C
    Allergy; 2012 Feb; 67(2):242-7. PubMed ID: 22126416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The promiscuity of immunoglobulin E binding to peanut allergens, as determined by Western blotting, correlates with the severity of clinical symptoms.
    Lewis SA; Grimshaw KE; Warner JO; Hourihane JO
    Clin Exp Allergy; 2005 Jun; 35(6):767-73. PubMed ID: 15969668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific immunoglobulin E antibodies to peanut over time in relation to peanut intake, symptoms and age.
    van Odijk J; Bengtsson U; Borres MP; Hulthén L; Ahlstedt S
    Pediatr Allergy Immunol; 2004 Oct; 15(5):442-8. PubMed ID: 15482520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tree nut- and sesame-specific IgE do not decrease from baseline with peanut oral immunotherapy (OIT).
    Bird JA; Kulis M; Burk CM; Vickery BP; Jones SM; Burks W
    Ann Allergy Asthma Immunol; 2012 Dec; 109(6):470-1. PubMed ID: 23176890
    [No Abstract]   [Full Text] [Related]  

  • 20. [Peanut allergy].
    Rasmussen KB; Jensen VB
    Ugeskr Laeger; 2002 Mar; 164(10):1366-7. PubMed ID: 11894432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.